Skip to main content

Biocapped Nanoparticles are More Bioactive to HeLa Cells than its Chemical Counterpart

Buy Article:

$107.14 + tax (Refund Policy)

In the present study we synthesized silver nanoparticles by conventional way of using citrate reduction as well as by green route synthesis using common bacteria Escherichia coli to demonstrate cytotoxicity and cell cycle regulation on cultured human HeLa cells. We employed cell morphology and apoptosis study, cell viability assay, cell cycle analysis and statistical analysis to compare the efficacy of two silver nanoparticles obtained from two different sources having same optical properties. Studies suggested that biocapped nanoparticles, which were synthesized using bacterial route, have more cell killing ability than its chemical counterpart. Furthermore, absence of nuclear fragmentation confirmed non-apoptotic cell death and FACS study supports the same along with additional information about the arrested HeLa cell growth at S-phase of cell cycle.

Keywords: CAPPING MATERIALS; CELL CYCLE; CYTOTOXICITY; HELA; SILVER NANOPARTICLES

Document Type: Research Article

Publication date: 01 August 2013

More about this publication?
  • Advanced Science, Engineering and Medicine (ASEM) is a science, engineering, technical and medical journal focused on the publishing of peer-reviewed multi-disciplinary research articles dealing with all fundamental and applied research aspects in the areas of (1) Physical Sciences, (2) Engineering, (3) Biological Sciences/Health Sciences, (4) Medicine, (5) Computer and Information Sciences, (6) Mathematical Sciences, (7) Agriculture Science and Engineering, (8) Geosciences, and (9) Energy/Fuels/Environmental/Green Science and Engineering.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content